新型口服抗凝剂治疗患者的临床管理

唐亮; 胡豫

doi:10.13201/j.issn.1004-2806.2017.01.001

新型口服抗凝剂治疗患者的临床管理

唐亮,
胡豫^,

- 华中科技大学同济医学院附属协和医院血液病研究所(武汉, 430022)

详细信息

通讯作者: 胡豫,E-mail:dr_huyu@126.com

中图分类号: R554

收稿日期: 2016-11-20

The clinical management of patients with new oral anticoagulant therapy

TANG Liang,
HU Yu^,

More Information

Corresponding author: HU Yu, E-mail: dr_huyu@126.com

Received Date: 20 November 2016

摘要

- 新型口服抗凝剂 /
- 逆转制剂 /
- 急诊手术 /
- 出血 /
- 血栓性疾病
- new oral anticoagulant /
- reversal agent /
- emergency operation /
- hemorrhage /
- thrombotic disease

HTML全文

参考文献(19)

[1]	Baumann Kreuziger LM,Morton CT,Dries DJ.New anticoagulants:A concise review[J].J Trauma Acute Care Surg,2012,73:983-992.
[2]	Yeh CH,Fredenburgh JC,Weitz JI.Oral direct factor Xa inhibitors[J].Circ Res,2012,111:1069-1078.
[3]	Yaghi S,Kamel H,Elkind MS.Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke[J].Neurology,2015,85:1078-1084.
[4]	Fareed J,Thethi I,Hoppensteadt D.Old versus new oral anticoagulants:focus on pharmacology[J].Ann Rev Pharmacol Toxicol,2012,52:79-99.
[5]	Skaistis J,Tagami T.Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and vitamin K antagonists:a systematic review and meta-analysis[J].PLoS One,2015,10:e0137444.
[6]	Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361:1139-1151.
[7]	Romualdi E,Donadini MP,Ageno W.Oral rivaroxaban after symptomatic venous thromboembolism:the continued treatment study(EINSTEIN-extension study)[J].Expert Rev Cardiovasc Ther,2011,9:841-844.
[8]	Franchini M,Bonfanti C,Mannucci PM.Management of bleeding associated with new oral anticoagulants[J].Semin Thromb Hemost,2015,41:788-801.
[9]	Pinho-Gomes AC,Hague A,Ghosh J.Management of novel oral anticoagulants in emergency and trauma surgery[J].Surgeon,2016,14:234-239.
[10]	Favaloro EJ,Lippi G.The new oral anticoagulants and the future of haemostasis laboratory testing[J].Biochem Med,2012,22:329-341.
[11]	van Ryn J,Stangier J,Haertter S,et al.Dabigatran etexilate——a novel,reversible,oral direct thrombin inhibitor:interpretation of coagulation assays and reversal of anticoagulant activity[J].Thromb Haemost,2010,103:1116-1127.
[12]	Barrett YC,Wang Z,Frost C,et al.Clinical laboratory measurement of direct factor Xa inhibitors:anti-Xa assay is preferable to prothrombin time assay[J].Thromb Haemost,2010,104:1263-1271.
[13]	Enriquez A,Lip GY,Baranchuk A.Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants[J].Europace,2016,18:955-964.
[14]	Stangier J,Stahle H,Rathgen K,et al.Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects[J].Clin Pharmacokinet,2008,47:47-59.
[15]	Crowther M,Crowther MA.Antidotes for novel oral anticoagulants:current status and future potential[J].Arterioscler Thromb Vasc Biol,2015,35:1736-1745.
[16]	Milling TJ Jr,Refaai MA,Goldstein JN,et al.Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate:exploratory analyses of two randomized,plasma-controlled studies[J].Ann Emerg Med,2016,67:96-105.
[17]	Pollack CV Jr,Reilly PA,Eikelboom J,et al.Idarucizumab for dabigatran reversal[J].N Engl J Med,2015,373:511-520.
[18]	Gomez-Outes A,Suarez-Gea ML,Lecumberri R,et al.Specific antidotes in development for reversal of novel anticoagulants:a review[J].Recent Pat Cardiovasc Drug Discov,2014,9:2-10.
[19]	Lu G,DeGuzman FR,Hollenbach SJ,et al.A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa[J].Nat Med,2013,19:446-451.